

ORIGINAL RESEARCH

# Combined Influence of Waist and Hip Circumference on Risk of Death in a Large Cohort of European and Australian Adults

Adrian J. Cameron, PhD\*; Helena Romaniuk, PhD\*; Liliana Orellana, PhD; Jean Dallongeville, PhD; Annette J. Dobson, PhD; Wojciech Drygas, MD; Marco Ferrario, MD; Jean Ferrieres, MD; Simona Giampaoli, MD; Francesco Gianfagna, MD; Licia Iacoviello, PhD; Pekka Jousilahti, PhD; Frank Kee, MD; Marie Moitry, MD; Teemu J. Niiranen, MD; Andrzej Pająk, PhD; Luigi Palmieri, PhD; Tarja Palosaari, MSc; Männistö Satu, PhD; Abdonas Tamosiunas, PhD; Barbara Thorand, PhD; Ulla Toft, PhD; Diego Vanuzzo, MD; Salomaa Veikko, MD; Giovanni Veronesi, PhD; Tom Wilsgaard, PhD; Kari Kuulasmaa, PhD; Stefan Söderberg, PhD

**BACKGROUND:** Waist circumference and hip circumference are both strongly associated with risk of death; however, their joint association has rarely been investigated.

**METHODS AND RESULTS:** The MONICA Risk, Genetics, Archiving, and Monograph (MORGAM) Project was conducted in 30 cohorts from 11 countries; 90 487 men and women, aged 30 to 74 years, predominantly white, with no history of cardiovascular disease, were recruited in 1986 to 2010 and followed up for up to 24 years. Hazard ratios were estimated using sex-specific Cox models, stratified by cohort, with age as the time scale. Models included baseline categorical obesity measures, age, total and high-density lipoprotein cholesterol, systolic blood pressure, antihypertensive drugs, smoking, and diabetes mellitus. A total of 9105 all-cause deaths were recorded during a median follow-up of 10 years. Hazard ratios for all-cause death presented J- or U-shaped associations with most obesity measures. With waist and hip circumference included in the same model, for all hip sizes, having a smaller waist was strongly associated with lower risk of death, except for men with the smallest hips. In addition, among those with smaller waists, hip size was strongly negatively associated with risk of death, with ~20% more people identified as being at increased risk compared with waist circumference alone.

**CONCLUSIONS:** A more complex relationship between hip circumference, waist circumference, and risk of death is revealed when both measures are considered simultaneously. This is particularly true for individuals with smaller waists, where having larger hips was protective. Considering both waist and hip circumference in the clinical setting could help to best identify those at increased risk of death.

**Key Words:** hip circumference ■ mortality ■ obesity ■ waist circumference

The prevalence of obesity is high or rapidly increasing in most countries, with serious health and economic consequences.<sup>1</sup> Body mass index (BMI) is the most commonly used measure of obesity; however, it does not capture the differential effects of adipose tissue from different parts of the body<sup>2–8</sup>

or visceral and subcutaneous adipose tissue.<sup>9</sup> Body shape differences mean that people with the same BMI can vary widely in their body fat distribution.<sup>10</sup> BMI also does not distinguish between fat mass and fat-free mass, the latter having a strong inverse relationship with morbidity and mortality.<sup>8</sup> The cost of the

Correspondence to: Adrian J. Cameron, PhD, Global Obesity Centre, Institute for Health Transformation, Deakin University, 221 Burwood Hwy, Burwood, VIC 3125, Australia. E-mail: adrian.cameron@deakin.edu.au

Supplementary Materials for this article are available at <https://www.ahajournals.org/doi/suppl/10.1161/JAHA.119.015189>

\*Prof Cameron and Dr Romaniuk contributed equally to this work.

For Sources of Funding and Disclosures, see page 13.

© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

JAHA is available at: [www.ahajournals.org/journal/jaha](http://www.ahajournals.org/journal/jaha)

## CLINICAL PERSPECTIVE

### What Is New?

- To the best of our knowledge, this is the most comprehensive investigation of the risk of death associated with different combinations of waist circumference and hip circumference, using data from >90 000 individuals (from 11 countries) who were followed up for up to 24 years.

### What Are the Clinical Implications?

- Among those with smaller waists (who would not normally have been identified as being at higher risk of death on the basis of their body size), having smaller hips was strongly associated with increased risk of death.
- Considering both waist and hip circumference simultaneously identifies almost 20% more people as being at higher risk of death compared with using waist circumference alone, and is a simple and cost-effective way of identifying body shapes associated with increased risk of premature death.

## Nonstandard Abbreviations and Acronyms

<b>ABSI</b>	a body shape index
<b>BMI</b>	body mass index
<b>CVD</b>	cardiovascular disease
<b>HC</b>	hip circumference
<b>MORGAM</b>	MONICA Risk, Genetics, Archiving, and Monograph Project
<b>WC</b>	waist circumference
<b>WHR</b>	waist/hip ratio

imaging methods required to accurately assess fat distribution is prohibitive in many settings. From a public health perspective, it is therefore important to identify simple anthropometric measures that reflect adipose tissue distribution and are closely related to morbidity and premature death.

Waist circumference (WC) and hip circumference (HC) are commonly used and easily understood measures of abdominal (upper-body) and gluteofemoral (lower-body) body size, respectively. WC is primarily a measure of visceral/ectopic and subcutaneous adipose tissue around the waist, whereas HC measures both adipose tissue and lower-body muscle mass. Numerous studies have shown that larger WC is strongly related to morbidity and premature death, while there is some evidence that larger HC is protective for these same outcomes.<sup>2,6,8,9,11</sup> The effects of different fat depots in the upper and lower body

are increasingly explained by variation in lipid storage and release<sup>11,12</sup> and the secretion of adipose tissue-related proteins.<sup>5,11</sup> Given their opposite relationships with metabolic health, the ratio of WC to HC (WHR) was conceptualized as an overall measure of obesity,<sup>13</sup> with the waist/height ratio also proposed as a way of capturing the distribution of body fat.<sup>14,15</sup> WHR and waist/height ratio have a simple interpretation when the relationship between the 2 variables is linear, but lack interpretation otherwise.<sup>16</sup> Furthermore, they can be identical for individuals of vastly different body shape.<sup>17</sup> There is no conclusive evidence that WC alone or WHR is more strongly related to risk of premature death than BMI.<sup>18,19</sup> Both, however, are predictors of death when added to a model also including BMI, meaning they are clearly identifying different components of obesity-related risk.<sup>18</sup> “A body shape index” (ABSI) that incorporates WC, height, and BMI has also been proposed in an attempt to identify an optimal body size measure associated with mortality.<sup>10</sup>

A 2013 systematic review identified only 5 studies predicting premature death using statistical models that included separate measures of both WC and HC.<sup>7</sup> In each case, the model including both measures was superior to a model including only one of them. These were single population studies with either a maximum follow-up of 12 years or <1500 deaths.

We aimed to conduct a novel assessment of the joint association of HC and WC with all-cause and cardiovascular disease (CVD) mortality outcomes, stratified by sex, using a large, multicountry cohort with long follow-up. We also report on the association between other more commonly used measures of body shape with mortality.

## METHODS

### Data Sharing

Details of data sharing arrangements and access to MONICA Risk, Genetics, Archiving, and Monograph (MORGAM) Project data are described in the following article: <https://doi.org/10.1093/ije/dyh327>. Please also see <http://www.thl.fi/morgam>.

### Study Population

The MORGAM Project is an ongoing multinational, collaborative study of prospective cohorts set up to investigate CVD.<sup>20</sup> Participating centers in each country recruited cohorts by taking random samples of geographically defined populations at different time periods, with standardized risk factors measured at baseline at enrollment and participants followed up for death. Details of MORGAM cohorts and data quality assessments are documented online,<sup>21,22</sup> with data

harmonized according to the Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA) and MORGAM manuals.<sup>21,23,24</sup>

Our study is based on data from 30 MORGAM cohorts from 17 participating centers located in 10 European countries plus Australia, which included 111 318 participants recruited between 1986 and 2010 who were followed up for up to 24 years. Participants were excluded if they were aged <30 years (n=6647; 6.0%) or ≥75 years (n=1863; 1.7%) at baseline, had missing information on follow-up period (n=473; 0.42%), had history of CVD (n=4916; 4.4%) or history of CVD was unknown (n=589; 0.53%), with some participants excluded for multiple reasons. Of the 97 189 (87.3%) participants eligible for this study, 6702 (6.9%) were excluded as they had incomplete baseline data for CVD risk factors. Our final analysis sample included 90487 participants (42792 women), who were predominantly white, with a median follow-up period of 10 years. Cohort characteristics are summarized by participating center and sex in Table 1. Each MORGAM participating center was responsible for ethical approval and patient consent, according to local rules at the time of study enrollment.

## End Points

Two end points were defined, all-cause and CVD death, via linkage to national or regional death registries. The follow-up of a person continued until the earliest one of the following events occurred: death; end of fixed follow-up period of the cohort; withdrew from study; or lost to follow-up. Only 1.1% of the analysis sample withdrew or was lost to follow-up. CVD death was defined as death from coronary heart disease or stroke, in addition to unclassifiable deaths where there was insufficient evidence for coronary origin. The diagnostic classification was based on validation of the cause of each death or on the *International Classification of Diseases (ICD)* codes of the routine death registration. Slight variation was present in *ICD* codes used because of local *ICD* coding practices (see description of MORGAM cohorts<sup>22</sup> for more details).

## Baseline Measurements

Participants' measures were collected at enrollment. Anthropometric measurements included weight in kilograms, and height, WC, and HC in meters.<sup>21</sup> BMI was calculated as weight/height<sup>2</sup>. WHR and waist/height ratio were calculated as WC/HC and WC/height, respectively. ABSI was calculated as follows: WC/(BMI<sup>2/3</sup>×height<sup>1/2</sup>). Blood pressure was measured as the mean of the first 2 measurements taken in a sitting position using the right arm and using a

standard or random zero sphygmomanometer, or an automated device, after a 5-minute rest, except in the United Kingdom and 3 French cohorts, in which blood pressure was measured only once using an automated device.<sup>21</sup> Total serum cholesterol and high-density lipoprotein cholesterol were analyzed in serum or plasma samples by local laboratories.<sup>21</sup> Diabetes mellitus, use of antihypertensive drugs, and smoking of cigarettes, cigars/cigarillos, or pipes were self-reported. History of CVD was identified from documentation (ie, population-based coronary event or stroke registers, person's medical records, a hospital discharge register, or other health information system) or self-reported history of myocardial infarction or stroke, including angina pectoris when the data collected did not permit its separation from myocardial infarction.

## Statistical Analysis

Anthropometric measures were categorized into 6 groups based on sex-specific sample means and SDs of all available data (<−1 SD below the mean, −1 to <−0.5 SDs below the mean, ≥−0.5–≤0.5 SDs from the mean, >0.5–1 SD above the mean, >1–2 SDs above the mean, and >2 SDs above the mean). The ranges of values for the categories are shown in Table S1.

Associations between the categorical anthropometric measures and the risk of all-cause and cardiovascular death were estimated separately for men and women using Cox proportional-hazards models, stratified by cohort, with age as the time scale, after partial and further adjustment. These associations were estimated in models including each individual anthropometric measure or a model including both WC and HC. *Partially adjusted models* included age at baseline (<50, 50–<55, 55–<60, 60–<65, 65–<70, and 70–<75 years). *Further adjusted models* included age and cardiovascular risk factors in the current version of the Framingham Risk Score,<sup>25</sup> all measured at baseline: log of total cholesterol (mmol/L), log of high-density lipoprotein cholesterol (mmol/L), systolic blood pressure (mm Hg), taking hypertension drugs (yes/no), current daily smoker (yes/no), and diabetes mellitus (yes/no). In the further adjusted model, interactions between baseline age and baseline measures, including anthropometric measures, were tested and retained if  $P < 0.001$ . Main and interaction effects were tested using the Wald test. For models including both WC and HC, we estimated the hazard ratios only for feasible combinations of these body measurements (observed in >0.1% of the sample [Table S2]). The proportional-hazards assumption was checked using Schoenfeld residuals.

We performed complete case analyses, including all participants who had no missing data for all baseline

**Table 1. MORGAM Cohort Characteristics and Number of All-Cause and Cardiovascular Deaths by MORGAM Participating Center and Sex**

Country	Participating Center	No. of Cohorts*	Age Range at Baseline, y	Survey Period	No. of Subjects		Mean (SD) Age at Baseline, y		Median (IQR) Follow-Up, y		All-Cause Deaths, n		Cardiovascular Deaths, n	
					Women	Men	Women	Men	Women	Men	Women	Men	Women	Men
Australia	Newcastle	2	30-70	1988-1994	1541	1468	52.8 (10.6)	53.6 (10.6)	4.5 (5.1)	4.7 (5.2)	47	85	11	22
Denmark	DAN-MONICA	2	30, 40, 50, 60 or 70†	1986-1992	1527	1482	49.5 (12.5)	49.4 (12.4)	19.7 (5.2)	19.6 (5.5)	364	438	116	151
Finland	FINRISK	4	30-74	1987-2002	11 373	10 250	48.2 (10.7)	48.7 (11.0)	13.9 (10.0)	13.9 (10.0)	932	1526	257	505
France	PRIME/Strasbourg	1	48-60	1991-1993	0	2325		54.7 (2.9)		10.0 (0.0)		130		23
France	PRIME/Toulouse	1	49-60	1991-1993	0	2402		54.9 (2.8)		10.0 (0.0)		89		14
France	PRIME/Lille	1	49-64	1991-1993	0	2333		55.1 (2.9)		10.0 (0.0)		141		31
Germany	MONICA/KORA Augsburg	3	30-74	1989-2001	5784	5659	51.6 (12.5)	51.7 (12.7)	13.8 (9.1)	13.6 (8.8)	640	1039	168	340
Italy	Brianza	2	30-66	1989-1994	1355	1276	47.9 (10.0)	48.9 (10.1)	15.1 (4.6)	15.0 (4.6)	94	168	19	32
Italy	Friuli	3	30-65	1989-1996	1564	1515	48.1 (9.4)	47.7 (9.5)	4.6 (5.3)	4.6 (5.3)	31	51	3	5
Italy	Moli-sani	1	34-74	2005-2010	11 267	9755	53.3 (10.2)	54.0 (10.3)	4.3 (1.9)	4.3 (1.9)	86	200	10	24
Italy	Rome	3	30-74	1993-1996	2358	1422	52.6 (12.0)	50.6 (11.9)	10.3 (1.5)	10.3 (2.3)	127	139	34	35
Lithuania	Kaunas	1	33-65	1992-1993	576	546	49.3 (8.6)	49.6 (8.7)	21.1 (0.8)	20.9 (6.2)	76	168	17	35
Norway	Tromsø	1	50-74	1994-1995	2785	2193	63.8 (6.0)	63.7 (5.6)	15.8 (0.4)	15.7 (4.0)	690	793	196	240
Poland	Krakow	1	34-65	1992-1993	528	485	49.7 (8.6)	49.8 (8.8)	6.5 (0.0)	6.5 (0.1)	9	36	0	11
Poland	Warsaw	1	34-64	1993	643	660	48.4 (8.2)	48.9 (8.4)	5.7 (0.5)	5.7 (0.6)	12	27	1	2
Sweden	Northern Sweden	2	30-74	1990-1994	1491	1387	49.5 (11.5)	49.4 (11.4)	17.9 (4.0)	17.9 (4.0)	214	281	83	91
United Kingdom	PRIME/Belfast	1	49-60	1991-1994	0	2537		54.7 (2.9)		18.0 (1.6)		472		101
Total		30	30-74	1986-2010	42 792	47 695	51.6 (11.3)	52.3 (10.3)	9.6 (10.8)	10.0 (9.9)	3322	5783	915	1662

DAN-MONICA indicates Danish-Multinational Monitoring of Trends and Determinants in Cardiovascular Disease; IQR, interquartile range; KORA, Cooperative Research in the study Region of Augsburg;

MONICA, Monitoring of Trends and Determinants in Cardiovascular Disease; MORGAM, MONICA Risk, Genetics, Archiving, and Monograph; PRIME, Prospective Epidemiological Study of Myocardial Infarction.

\*Cohorts are defined as random samples on geographically defined populations at different time periods.

†Participants recruited when they were aged ≈30, 40, 50, 60, or 70 years.

**Table 2. Baseline Characteristics by Sex and Survival Status**

Baseline Characteristic	Women				Men			
	All (N=42 792)	Alive at End of Study (N=39 470)*	Died During Follow-Up (N=3322)	P Value†	All (N=47 695)	Alive at End of Study (N=41 912)*	Died During Follow-Up (N=5783)	P Value†
<b>Demographics</b>								
Age, mean (SD), y	51.6 (11.3)	50.7 (11.0)	61.3 (9.5)	<0.0001	52.3 (10.3)	51.3 (10.1)	59.4 (9.3)	<0.0001
Age, y				<0.0001				<0.0001
<50	19 516 (45.6)	19 065 (48.3)	451 (13.6)		17 282 (36.2)	16 498 (39.4)	784 (13.6)	
50–<55	5870 (13.7)	5588 (14.2)	282 (8.5)		9869 (20.7)	9035 (21.6)	834 (14.4)	
55–<60	6224 (14.5)	5730 (14.5)	494 (14.9)		10 189 (21.4)	8838 (21.1)	1351 (23.4)	
60–<65	5421 (12.7)	4630 (11.7)	791 (23.8)		5047 (10.6)	3946 (9.4)	1101 (19.0)	
65–<70	3364 (7.9)	2754 (7.0)	610 (18.4)		3197 (6.7)	2322 (5.5)	875 (15.1)	
70–<75	2397 (5.6)	1703 (4.3)	694 (20.9)		2111 (4.4)	1273 (3.0)	838 (14.5)	
<b>Body measurements</b>								
Body mass index, mean (SD), kg/m <sup>2</sup>	26.9 (5.1)	26.9 (5.1)	27.6 (5.5)	<0.0001	27.1 (3.8)	27.1 (3.8)	27.0 (4.2)	0.353
Body mass index, kg/m <sup>2</sup>				<0.0001				<0.0001
<–1 SD below the mean	5935 (13.9)	5518 (14.0)	417 (12.6)		6652 (13.9)	5655 (13.5)	997 (17.2)	
–1 to <–0.5 SDs below the mean	9126 (21.3)	8524 (21.6)	602 (18.1)		8667 (18.2)	7664 (18.3)	1003 (17.3)	
≥–0.5 to ≤0.5 SDs from the mean	16 325 (38.1)	15 106 (38.3)	1219 (36.7)		19 741 (41.4)	17 595 (42.0)	2146 (37.1)	
>0.5 to 1 SD above the mean	4780 (11.2)	4343 (11.0)	437 (13.2)		5964 (12.5)	5258 (12.5)	706 (12.2)	
>1 to 2 SDs above the mean	4859 (11.4)	4389 (11.1)	470 (14.1)		4944 (10.4)	4265 (10.2)	679 (11.7)	
>2 SDs above the mean (SD)	1767 (4.1)	1590 (4.0)	177 (5.3)		1727 (3.6)	1475 (3.5)	252 (4.4)	
Waist/hip ratio, mean (SD)	0.83 (0.08)	0.83 (0.08)	0.84 (0.07)	0.0014	0.94 (0.06)	0.94 (0.06)	0.95 (0.07)	<0.0001
Waist/hip ratio				<0.0001				<0.0001
<–1 SD below the mean	6148 (14.4)	5810 (14.7)	338 (10.2)		6513 (13.7)	5827 (13.9)	686 (11.9)	
–1 to <–0.5 SDs below the mean	8125 (19.0)	7526 (19.1)	599 (18.0)		9329 (19.6)	8294 (19.8)	1035 (17.9)	
≥–0.5 to ≤0.5 SDs from the mean	16 988 (39.7)	15 531 (39.3)	1457 (43.9)		17 944 (37.6)	15 899 (37.9)	2045 (35.4)	
>0.5 to 1 SD above the mean	5229 (12.2)	4741 (12.0)	488 (14.7)		6672 (14.0)	5795 (13.8)	877 (15.2)	

(Continued)

**Table 2. Continued**

Baseline Characteristic	Women				Men			
	All (N=42 792)	Alive at End of Study (N=39 470)*	Died During Follow-Up (N=3322)	P Value†	All (N=47 695)	Alive at End of Study (N=41 912)*	Died During Follow-Up (N=5783)	P Value†
>1 to 2 SDs above the mean	4618 (10.8)	4269 (10.8)	349 (10.5)		5917 (12.4)	5000 (11.9)	917 (15.9)	
>2 SDs above the mean	1684 (3.9)	1593 (4.0)	91 (2.7)		1320 (2.8)	1097 (2.6)	223 (3.9)	
A body shape index, mean (SD)§	0.076 (0.006)	0.076 (0.006)	0.076 (0.006)	<0.0001	0.080 (0.004)	0.080 (0.004)	0.082 (0.004)	<0.0001
A body shape index‡				<0.0001				<0.0001
<-1 SD below the mean	5992 (14.0)	5660 (14.3)	332 (10.0)		7045 (14.8)	6465 (15.4)	580 (10.0)	
-1 to <-0.5 SDs below the mean	8248 (19.3)	7714 (19.5)	534 (16.1)		7334 (15.4)	6673 (15.9)	661 (11.4)	
≥-0.5 to ≤0.5 SDs from the mean	16 983 (39.7)	15 488 (39.2)	1495 (45.0)		19 238 (40.3)	17 173 (41.0)	2065 (35.7)	
>0.5 to 1 SD above the mean	4818 (11.3)	4323 (11.0)	495 (14.9)		7129 (14.9)	6097 (14.5)	1032 (17.8)	
>1 to 2 SDs above the mean	4932 (11.5)	4560 (11.6)	372 (11.2)		5878 (12.3)	4725 (11.3)	1153 (19.9)	
>2 SDs above the mean	1819 (4.3)	1725 (4.4)	94 (2.8)		1071 (2.2)	779 (1.9)	292 (5.0)	
Waist/height ratio, mean (SD)	0.54 (0.09)	0.54 (0.09)	0.55 (0.09)	<0.0001	0.55 (0.06)	0.55 (0.06)	0.56 (0.07)	<0.0001
Waist/height ratio				<0.0001				<0.0001
<-1 SD below the mean	6862 (16.0)	6488 (16.4)	374 (11.3)		7140 (15.0)	6376 (15.2)	764 (13.2)	
-1 to <-0.5 SDs below the mean	8514 (19.9)	7922 (20.1)	592 (17.8)		8069 (16.9)	7187 (17.1)	882 (15.3)	
≥-0.5 to ≤0.5 SDs from the mean	15 219 (35.6)	13 961 (35.4)	1258 (37.9)		19 175 (40.2)	17 014 (40.6)	2161 (37.4)	
>0.5 to 1 SD above the mean	5264 (12.3)	4791 (12.1)	473 (14.2)		6307 (13.2)	5466 (13.0)	841 (14.5)	
>1 to 2 SDs above the mean	5290 (12.4)	4796 (12.2)	494 (14.9)		5432 (11.4)	4597 (11.0)	835 (14.4)	
>2 SDs above the mean	1643 (3.8)	1512 (3.8)	131 (3.9)		1572 (3.3)	1272 (3.0)	300 (5.2)	
Waist circumference, mean (SD), cm	85.7 (13.0)	85.6 (13.0)	87.4 (13.0)	<0.0001	95.2 (10.4)	95.0 (10.3)	96.4 (11.3)	<0.0001
Waist circumference				<0.0001				<0.0001
<-1 SD below the mean	6715 (15.7)	6322 (16.0)	393 (11.8)		6922 (14.5)	6103 (14.6)	819 (14.2)	

(Continued)

**Table 2. Continued**

Baseline Characteristic	Women				Men			
	All (N=42 792)	Alive at End of Study (N=39 470)*	Died During Follow-Up (N=3 322)	P Value†	All (N=47 695)	Alive at End of Study (N=41 912)*	Died During Follow-Up (N=5 783)	P Value†
-1 to < -0.5 SDs below the mean	8499 (19.9)	7899 (20.0)	600 (18.1)		8870 (18.6)	7895 (18.8)	975 (16.9)	
>-0.5 to ≤0.5 SDs from the mean	15 507 (36.2)	14 280 (66.2)	1227 (36.9)		18 641 (39.1)	16 583 (39.6)	2058 (35.6)	
>0.5 to 1 SD above the mean	5128 (12.0)	4669 (11.8)	459 (13.8)		6277 (13.2)	5492 (13.1)	785 (13.6)	
>1 to 2 SDs above the mean	5307 (12.4)	4815 (12.2)	492 (14.8)		5483 (11.5)	4599 (11.0)	884 (15.3)	
>2 SDs above the mean	1636 (3.8)	1485 (3.8)	151 (4.5)		1502 (3.1)	1240 (3.0)	262 (4.5)	
Hip circumference, mean (SD), cm	102.6 (10.1)	102.5 (10.1)	104.1 (11.0)	<0.0001	101.0 (7.6)	100.9 (7.5)	101.4 (8.2)	<0.0001
Hip circumference				<0.0001				<0.0001
<-1 SD below the mean	5716 (13.4)	5302 (13.4)	414 (12.5)		6643 (13.9)	5790 (13.8)	853 (14.8)	
-1 to <-0.5 SDs below the mean	8358 (19.5)	7809 (19.8)	549 (16.5)		8309 (17.4)	7388 (17.6)	921 (15.9)	
>-0.5 to ≤0.5 SDs from the mean	17 334 (40.5)	16 083 (40.7)	1251 (37.7)		19 383 (40.6)	17 220 (41.1)	2163 (37.4)	
>0.5 to 1 SD above the mean	5065 (11.8)	4632 (11.7)	433 (13.0)		6793 (14.2)	5892 (14.1)	901 (15.6)	
>1 to 2 SDs above the mean	4586 (10.7)	4095 (10.4)	491 (14.8)		5170 (10.8)	4457 (10.6)	713 (12.3)	
>2 SDs above the mean	1733 (4.0)	1549 (3.9)	184 (5.5)		1397 (2.9)	1165 (2.8)	232 (4.0)	
Other CVD risk factors								
Total cholesterol, mean (SD), mmol/L	5.83 (1.19)	5.78 (1.16)	6.49 (1.35)	<0.0001	5.80 (1.12)	5.77 (1.10)	6.02 (1.22)	<0.0001
Total cholesterol, median (IQR), mmol/L	5.70 (1.57)	5.66 (1.51)	6.40 (1.70)	<0.0001	5.70 (1.48)	5.70 (1.44)	5.90 (1.60)	<0.0001
HDL cholesterol, mean (SD), mmol/L	1.58 (0.39)	1.59 (0.39)	1.55 (0.43)	<0.0001	1.30 (0.35)	1.30 (0.34)	1.31 (0.40)	0.0033
HDL cholesterol, median (IQR), mmol/L	1.55 (0.50)	1.55 (0.49)	1.52 (0.56)	<0.0001	1.27 (0.44)	1.27 (0.43)	1.26 (0.48)	0.642
Systolic blood pressure, mean (SD), mm Hg	135 (22)	134 (21)	147 (24)	<0.0001	138 (19)	137 (19)	145 (22)	<0.0001
Taking antihypertensive drugs	7405 (17.3)	6584 (16.7)	821 (24.7)	<0.0001	6962 (14.6)	5866 (14.0)	1096 (19.0)	<0.0001

(Continued)

**Table 2. Continued**

Baseline Characteristic	Women			Men				
	All (N=42 792)	Alive at End of Study (N=39 470)*	Died During Follow-Up (N=3322)	P Value†	All (N=47 695)	Alive at End of Study (N=41 912)*	Died During Follow-Up (N=5783)	P Value†
Current daily smoker	8590 (20.1)	7681 (19.5)	909 (27.4)	<0.0001	13 955 (29.3)	11 539 (27.5)	2416 (41.8)	<0.0001
Diabetes mellitus	1769 (4.1)	1434 (3.6)	335 (10.1)	<0.0001	2259 (4.7)	1711 (4.1)	548 (9.5)	<0.0001

Data are given as number (percentage). CVD indicates cardiovascular disease; HDL, high-density lipoprotein; and IQR, interquartile range.

\*Participants censored at end of follow-up period.

†P values are for the comparison of participants who were alive at the end of the study with those who died during follow-up and were based on  $\chi^2$  tests for categorical measures and t tests and Wilcoxon rank-sum test for continuous measures, summarized by the mean and median, respectively.

‡Body mass index is the weight in kilograms divided by the square of the height in meters.

§A body shape index is waist circumference in meters/(BMI)<sup>2/3</sup> × height in meters<sup>1/2</sup>.

measures used in the analyses. We compared the characteristics of participants included in, and excluded from, the analysis sample (Table S3). We assessed potential collinearity (and interaction) between WC and HC by creating a single joint measure of WC and HC, with 21 categories for women and 22 categories for men representing all WC and HC combinations. Some categories were combined to ensure sufficient numbers. The reference category was defined as both HC and WC being  $\geq -0.5$  to  $\leq 0.5$  SDs from the mean. For both men and women, estimated hazard ratios for levels of the single joint measure were comparable to those obtained from models including WC and HC as separate measures (results not presented). Further sensitivity analyses were performed for all-cause death, (1) excluding those who died <2 years from baseline, (2) excluding those reporting diabetes mellitus at baseline, and (3) including an interaction between daily smokers at baseline and each anthropometric measure. All statistical analyses were run using Stata 15.

## RESULTS

### Characteristics of Study Participants

The mean (SD) age of participants was 52.0 (10.8) years, and 52.7% were men. Anthropometric and other baseline measures are summarized by sex and survival status in Table 2. During a median (interquartile range) follow-up of 10.0 (10.4) years, 9105/90 487 (10.1%) participants died from all causes, and 2577 (2.8%) died from cardiovascular causes. Follow-up periods and mortality rates are summarized by participating center and sex in Table 1.


Characteristics of participants included in the analysis and those excluded because of incomplete data were similar (Table S3), except that the analysis sample included a higher proportion of men (52.7% versus 44.3%) and participants aged <50 years (40.7% versus 31.8%).

### Associations Between Individual Anthropometric Measures and Death

All anthropometric measures were strongly associated with risk of all-cause and CVD death, for both men and women, in both the partially and further adjusted models (Tables S4 through S7). Estimated adjusted hazard ratios for all-cause and CVD death, for each individual anthropometric measure relative to the reference category ( $\geq -0.5$  to  $\leq 0.5$  SDs around mean), are shown by sex in Figure 1.

Further adjusted hazard ratios for all-cause death followed different patterns across levels of the obesity measures. A U-shaped pattern (increased risk for both the lowest and highest levels of the measure) was observed for BMI and HC in men and women and for WC





**Figure 1. Risk of death, according to obesity measures, by sex and cause of death, estimated after adjustment for cardiovascular risk factors.**

Hazard ratios for all-cause (A and B) and cardiovascular (C and D) death by sex, with 95% CIs, are shown for each obesity measure: body mass index (BMI; weight in kilograms divided by the square of the height in meters), weight/hip ratio (WHR), a body shape index (ABSI; waist circumference in meters/[BMI<sup>2/3</sup>×height in meters<sup>1/2</sup>]), weight/height ratio (WHtR), waist circumference, and hip circumference. Vertical lines indicate 95% CIs. Reference category for each obesity measure was ≥−0.5 SDs to ≤0.5 SDs from the sample sex-specific mean. Risks were estimated from Cox proportional hazards models, stratified by cohort, and adjusted for age at baseline, log of total cholesterol (mmol/L), log of high-density lipoprotein (HDL) cholesterol (mmol/L), systolic blood pressure (mm Hg), taking antihypertensive drugs, current daily smoker (cigarettes, cigars/cigarillos, or pipe), diabetes mellitus, and all interactions between age and baseline measures that were statistically significant (*P*<0.001). <sup>†</sup>Additionally adjusted for an interaction between age at baseline and log of HDL cholesterol (mmol/L). <sup>‡</sup>Additionally adjusted for interaction between age at baseline and systolic blood pressure. <sup>§</sup>Additionally adjusted for interaction between age at baseline and current daily smoker.


in men. Risk increased monotonically with ABSI and WHR, with reduced risk for some categories below the mean. A J-shaped association was seen for waist/height ratio for both men and women and for WC in women.

The further adjusted associations between the anthropometric measures and CVD death followed an essentially similar pattern, with wider CIs for both men and women.

### Associations Between WC and HC Measures and Death

When both WC and HC were included as predictors of all-cause death in the same partially or further adjusted model (reference category ≥−0.5 to ≤0.5 SDs

from the mean), both variables remained strongly associated with risk of death (*P*<0.0001; Tables S4 and S5). There was a monotonic relationship between WC and risk of death for both women and men. For women, further adjusted hazard ratios increased from 0.79 (95% CI, 0.68–0.91) for WC <−1 SD below the mean to 2.16 (95% CI, 1.72–2.71) for WC >2 SDs above the mean. For men, the further adjusted hazard ratios increased from 0.90 (95% CI, 0.81–0.99) to 1.74 (95% CI, 1.46–2.08) in the smallest and largest WC categories, respectively. In the same model, lower HC categories were associated with increased risk in women (<−1 SD below the mean: 1.72 [95% CI, 1.49–1.98]; −1 to <−0.5 SDs below the mean: 1.27 [95% CI, 1.14–1.42]) and men (<−1 SD below the mean: 1.52 [95% CI, 1.37–1.69]; −1 to <−0.5 SDs



**Figure 2. Risk of death, according to waist circumference within hip circumference levels, by sex and cause of death, estimated after adjustment for cardiovascular risk factors.**

Hazard ratios for all-cause (A and B) and cardiovascular (C and D) death by sex, with 95% CIs, are shown for all feasible combinations of waist circumference and hip circumference. Vertical lines indicate 95% CIs. Reference category was  $\geq -0.5$  SDs to  $\leq 0.5$  SDs from the sample sex-specific mean for both waist circumference and hip circumference. Risks were estimated from Cox proportional hazards models, stratified by cohort, and adjusted for age at baseline, log of total cholesterol (mmol/L), log of high-density lipoprotein (HDL) cholesterol (mmol/L), systolic blood pressure (mm Hg), taking antihypertensive drugs, current daily smoker (cigarettes, cigars/cigarillos, or pipe), diabetes mellitus, and all interactions between age and baseline measures that were statistically significant ( $P < 0.001$ ). <sup>†</sup>Additionally adjusted for an interaction between age at baseline and log of HDL cholesterol (mmol/L). <sup>#</sup>Additionally adjusted for an interaction between age at baseline and systolic blood pressure. <sup>&</sup>Additionally adjusted for an interaction between age at baseline and current daily smoker.

below the mean: 1.13 [95% CI, 1.04–1.23]), with no increased risks for HC categories above the reference level.


We report the combined influence of HC and WC on risk of death in 2 ways, conditional on HC levels (Figure 2) and conditional on WC levels (Figure 3). Both figures show the estimated adjusted hazard ratios for feasible combinations of WC and HC relative to the reference category ( $\geq -0.5$  to  $\leq 0.5$  SDs from the mean for both WC and HC). Figure 2 shows a strong, monotonic relationship between WC and risk of death for all HC categories, with smaller WC associated with lower risk of death, except for those with the smallest hips ( $< -1$  SD below the mean in men). Figure 3 shows the pattern when considering the impact of HC for different levels of WC. For both men and women with a smaller waist (WC  $\leq 1$  SD above the mean:  $\leq 98.8$  cm in

women and  $\leq 105.7$  cm in men), larger hips were associated with a reduction in risk. For WC  $> 1$  SD above the mean, risk of death did not change with HC for men or women.

Similar patterns were seen for CVD death (Tables S6 and S7, Figures 1 through 3).

### Sensitivity Analyses

Estimates were robust to excluding participants who died within 2 years from baseline ( $n=640$ ; 0.7%) or those reporting diabetes mellitus at baseline ( $n=4028$ ; 4.5%) (estimates not presented). We assessed period effect; by adding decade of enrollment to the further adjusted models. We found no statistical evidence of a period effect for both men and women (estimates not presented). To investigate



**Figure 3. Risk of death, according to hip circumference within waist circumference levels, by sex and cause of death, estimated after adjustment for cardiovascular risk factors.**

Hazard ratios for all-cause (A and B) and cardiovascular (C and D) death by sex, with 95% CIs, are shown for all feasible combinations of waist circumference and hip circumference. Vertical lines indicate 95% CIs. Reference category was  $\geq -0.5$  SDs to  $\leq 0.5$  SDs from the sample sex-specific mean for both waist circumference and hip circumference. Risks were estimated from Cox proportional hazards models, stratified by cohort, and adjusted for age at baseline, log of total cholesterol (mmol/L), log of high-density lipoprotein (HDL) cholesterol (mmol/L), systolic blood pressure (mm Hg), taking antihypertensive drugs, current daily smoker (cigarettes, cigars/cigarillos, or pipe), diabetes mellitus, and all interactions between age and baseline measures that were statistically significant ( $P < 0.001$ ). <sup>†</sup>Additionally adjusted for an interaction between age at baseline and log of HDL cholesterol (mmol/L). <sup>‡</sup>Additionally adjusted for an interaction between age at baseline and systolic blood pressure. <sup>§</sup>Additionally adjusted for an interaction between age at baseline and current daily smoker.

whether the U- or J-shaped relationship between mortality and some of the anthropometric measures could be explained by mortality due to diseases associated with smoking (which also affect anthropometric measures), we fitted models that additionally included baseline smoking status and the interaction between smoking and anthropometric measures. The adjusted estimates for nonsmokers and smokers are presented in Figure S1. Because the main aim of this analysis was to understand whether the shape of the association for the anthropometric categories was similar for smokers and nonsmokers, the hazard ratio estimates presented for smokers did not include the risk associated with smoking (ie, risk was estimated using main effect of anthropometric measure plus the interaction term between smoking and the anthropometric measure). The shapes of the relationships between the body measures and risk of death were similar.

## DISCUSSION

This study of >90 000 predominantly white adults followed up for up to 24 years provides evidence that it is important to consider measures of both upper- and lower-body adiposity when estimating risk of death. The most commonly used measures of obesity (BMI and WC) as well as HC displayed U- or J-shaped associations with risk of death from all causes. When both WC and HC were included together in models, a more nuanced and clearer picture was revealed, with 2 distinct clinical messages. First, WC was strongly positively associated with risk of death at all hip sizes, except among those with the smallest hips (who almost all have WC well below the mean). In addition, among those with smaller waists, hip size was strongly negatively associated with risk of death. Among the people with smaller waists, who would not normally be identified as being at higher risk of death, having

smaller hips was clearly associated with increased risk of death. In our sample, by considering both WC and HC, rather than just WC, an additional 19% of women and 18% of men would be identified as being at higher risk of death. These results demonstrate the value of considering body shape using both WC and HC, and contribute to the growing literature on the impact of body fat depots in different parts of the body on risk of death, as well as the evidence for the protective effects of fat-free mass.<sup>2,4,6,8,11</sup>

Like others<sup>10</sup>, we found that ABSI was a strong predictor of death. This suggests that ABSI could be useful in the research setting, particularly because it is a single measure of obesity. It may also have some value in clinical settings if simple calculators based on population norms were created. From a public health perspective, ABSI is likely to be less useful because of the inherent challenges in communicating messages about risk of death using a highly complex concept and measure.

Our findings add to the small but growing literature examining the combined effect of WC and HC as predictors of death. A 2013 literature review on the topic found 5 studies that all suggested the strength of associations between WC and death is underestimated without also considering HC.<sup>7</sup> Compared with these studies (and one published since),<sup>26</sup> our study used a larger, multicountry cohort with longer follow-up and a substantial number of deaths. Hazard ratios for combined categories of WC and HC have only previously been estimated in our earlier study among South Asian and African Mauritian.<sup>27</sup> The current finding that larger HC is protective only for people with smaller WC agrees with evidence from that Mauritian study. The stronger relationship between WC and HC and risk of death observed in Mauritius may be due to the considerably lower WCs observed in that population (median [interquartile range] WC, 90.5 [17.0] cm for survivors and 94.0 [17.0] cm for those who died from CVD in this sample compared with 79.5 [15.2] cm for survivors and 84.0 [15.5] cm for those who died from CVD in Mauritius).<sup>27</sup> It is possible that in the many populations worldwide that currently have a larger mean WC than observed in the historic MORGAM cohort, the protective effect of HC may be less pronounced. Further studies among populations with different prevalence of obesity at baseline will be important to confirm this hypothesis. Unfortunately, heterogeneity of findings across participating cohorts could not be tested within our analytical framework because of the small number of deaths in some, and different survey periods and age profiles.

Although the physiological basis for the opposing effects of WC and HC is not completely clear, some hypotheses for the protective effects of lower-body gluteofemoral adipose tissue, and the particularly

detrimental effects of visceral adipose tissue, have been put forward.<sup>11,12</sup> These include clear differences in the ability of the cells in different depots to store and release lipids and the secretion of proteins, such as leptin and adiponectin (positively associated), as well as inflammatory cytokines (negatively associated).<sup>11</sup> In addition to these metabolic differences, lower-body anthropometric measures are also capturing fat-free (muscle) mass in the thigh and buttocks. Greater muscle mass is likely to be indicative of greater levels of physical activity and less time sedentary, which are both protective against premature death,<sup>28,29</sup> whereas smaller hips could reflect overall smaller frame size or result from health conditions influenced by lifestyle behaviors. More important, although body shape changes with age, the associations observed were robust across all age groups (up to age 75 years). An extensive literature exists on the association between HC or thigh circumference (relative to WC) and a range of metabolic risk markers and disease outcomes, including dyslipidemia, hypertension, and diabetes mellitus,<sup>2-4</sup> in addition to the all-cause and CVD mortality observed here.

It is possible that strength training interventions that increase muscle in the hips or thighs without also increasing waist may reduce risk in addition to interventions that target reduction in WC. Although that hypothesis is untested, a Scandinavian study showed no reduction in risk of death among those who reduced their HC over time. That study, however, did not specifically assess the corresponding changes in WC for those who reduced their HC.<sup>26</sup> A Danish study found that the risk of death from small hips was partially attenuated by physical activity.<sup>30</sup>

Strengths of this study include the large sample size from 30 cohorts in 11 countries, the consistent methods for measurement of baseline factors and ascertainment of outcomes, and that findings were robust across multiple sensitivity analyses. Limitations include the inability to exclude participants with a diagnosis of cancer, respiratory disease, or abdominal distension (not measured) or pregnancy (recorded in <50% of cohorts), the absence of information on potential confounders, such as physical activity and sedentary behavior, the self-report of diabetes mellitus history, and the low incidence of CVD death observed. Furthermore, as all measures were collected at baseline, we were unable to investigate the variation in body measures and CVD risk factors over time and the relationship with the risk of death.

In conclusion, this study provides evidence that a more complex relationship between HC, WC, and risk of death is revealed when both measures are considered simultaneously. Considering both WC and HC in the clinical setting could help best identify those at increased risk of death.

## ARTICLE INFORMATION

Received November 12, 2019; accepted May 6, 2020.

### Affiliations

From the Global Obesity Centre, Institute for Health Transformation (A.J.C.), and Biostatistics Unit, Faculty of Health (H.R., L.O.), Deakin University, Geelong, Australia; Unité d'Epidémiologie et de Santé Publique, Inserm-U1167, Institut Pasteur de Lille, Lille, France (J.D.); School of Public Health, University of Queensland, Herston, Queensland, Australia (A.J.D.); Department of Epidemiology CVD Prevention and Health Promotion, Cardinal Wyszynski National Institute of Cardiology, Warsaw, Poland (W.D.); Department of Medicine and Surgery, Research Center in Epidemiology and Preventive Medicine, University of Insubria, Varese, Italy (M.F., F.G., L.I., G.V.); Department of Cardiology, Toulouse University School of Medicine, Toulouse, France (J.F.); Department of Cardiovascular, Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanità, Rome, Italy (S.G., L.P.); University of Insubria, Varese, Italy (F.G., L.I.); Mediterranea Cardiocentro, Napoli, Italy (F.G.); Department of Epidemiology and Prevention, Istituto di Ricovero e Cura a Carattere Scientifico Neuromed, Pozzilli, Italy (L.I.); Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland (P.J., T.J.N., T.P., M.S., S.V., K.K.); Centre for Public Health, Institute for Health Sciences, Queen's University, School of Medicine, Dentistry and Biomedical Sciences, Belfast, Northern Ireland (F.K.); Department of Public Health, University Hospital of Strasbourg, France (M.M.); Department of Epidemiology and Public Health, University of Strasbourg, France (M.M.); Department of Medicine, Turku University Hospital and University of Turku, Turku, Finland (T.J.N.); Department of Epidemiology and Population Studies, Jagiellonian University Medical College, Kraków, Poland (A.P.); Department of Population Studies, Institute of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania (A.T.); German Research Center for Environmental Health, Institute of Epidemiology, Helmholtz Zentrum München, Neuherberg, Germany (B.T.); Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark (U.T.); Cardiovascular Prevention Centre, Udine, Italy (D.V.); Department of Community Medicine, The Arctic University of Norway, Tromsø, Norway (T.W.); and Department of Public Health and Clinical Medicine, and Heart Centre, Umeå University, Umeå, Sweden (S.S.).

### Acknowledgments

Drs Cameron, Romaniuk, Orellana, and Söderberg were responsible for the conception and design of the work. Drs Cameron, Romaniuk, and Orellana were responsible for analysis of the data and initial drafting of the manuscript. All authors other than Drs Cameron, Romaniuk, and Orellana were responsible for acquisition of data. All authors were involved in revisions of the manuscript and interpretation of data and have approved the submitted version.

### Sources of Funding

This work was supported by the Medical Research Council London (grant G0601463 [80983]) and European Union FP7 project BiomarCaRE (grant HEALTH-F2-2011-278913), which supported the Monica Risk, Genetics, Archiving, and Monograph (MORGAM) Project. The activities of the MORGAM Data Centre have been sustained also by recent funding from European Union FP7 project Consortium on Health and Ageing: Network of Cohorts in Europe and the United States (HEALTH-F3-2010-242244). Dr Cameron is the recipient of an Australian Research Council Discovery Early Career Researcher Award (grant DE160100141). Dr Söderberg was supported by the Swedish Heart-Lung Foundation, the County Council of Västerbotten (grant ALF, VLL-548791), and Umeå University. All funders had no involvement in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. All researchers are independent of the funders and have had full access to all the statistical reports and tables in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. We are not aware of any conflicts of interest in relation to this work.

### Disclosures

None.

### Supplementary Materials

Tables S1–S7

Figure S1

## REFERENCES

1. Global Burden of Disease Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, Marczak L, Mokdad AH, Moradi-Lakeh M, Naghavi M, et al. Health effects of overweight and obesity in 195 countries over 25 years. *N Engl J Med*. 2017;377:13–27.
2. Sniijder MB, Zimmet PZ, Visser M, Dekker JM, Seidell JC, Shaw JE. Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the AusDiab Study. *Int J Obes Relat Metab Disord*. 2004;28:402–409.
3. Parker ED, Pereira MA, Stevens J, Folsom AR. Association of hip circumference with incident diabetes and coronary heart disease: the Atherosclerosis Risk in Communities study. *Am J Epidemiol*. 2009;169:837–847.
4. Canoy D, Boekholdt SM, Wareham N, Luben R, Welch A, Bingham S, Buchan I, Day N, Khaw K-T. Body fat distribution and risk of coronary heart disease in men and women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk cohort: a population-based prospective study. *Circulation*. 2007;116:2933–2943.
5. Borges MC, Oliveira IO, Freitas DF, Horta BK, Ong KK, Gigante DP, Barros AJD. Obesity-induced hypoadiponectinaemia: the opposite influences of central and peripheral fat compartments. *Int J Epidemiol*. 2017;46:2044–2055.
6. Biggaard J, Frederiksen K, Tjønneland A, Thomsen BL, Overvad K, Heitmann BL, Sorensen TIA. Waist and hip circumferences and all-cause mortality: usefulness of the waist-to-hip ratio? *Int J Obes Relat Metab Disord*. 2004;28:741–747.
7. Cameron AJ, Magliano DJ, Söderberg S. A systematic review of the impact of including both waist and hip circumference in risk models for cardiovascular diseases, diabetes and mortality. *Obes Rev*. 2013;14:86–94.
8. Heitmann BL, Frederiksen P. Thigh circumference and risk of heart disease and premature death: prospective cohort study. *Br Med J*. 2009;339:b3292.
9. Neeland IJ, Poirier P, Despres JP. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. *Circulation*. 2018;137:1391–1406.
10. Krakauer NY, Krakauer JC. A new body shape index predicts mortality hazard independently of body mass index. *PLoS One*. 2012;7:e39504.
11. Manolopoulos KN, Karpe F, Frayn KN. Gluteofemoral body fat as a determinant of metabolic health. *Int J Obes (Lond)*. 2010;34:949–959.
12. Piche ME, Vasani SK, Hodson L, Karpe F. Relevance of human fat distribution on lipid and lipoprotein metabolism and cardiovascular disease risk. *Curr Opin Lipidol*. 2018;29:285–292.
13. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Björntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. *Br Med J (Clin Res Ed)*. 1984;288:1401–1404.
14. Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. *Obes Rev*. 2012;13:275–286.
15. Ashwell M, Lejeune S, McPherson K. Ratio of waist circumference to height may be better indicator of need for weight management. *Br Med J*. 1996;312:377.
16. Allison DB, Paultre F, Goran MI, Poehlman ET, Heymsfield SB. Statistical considerations regarding the use of ratios to adjust data. *Int J Obes Relat Metab Disord*. 1995;19:644–652.
17. Molarius A, Seidell JC, Sans S, Tuomilehto J, Kuulasmaa K. Waist and hip circumferences, and waist-hip ratio in 19 populations of the WHO MONICA Project. *Int J Obes Relat Metab Disord*. 1999;23:116–125.
18. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, van der Schouw YT, Spencer E, Moons KGM, Tjønneland A, et al. General and abdominal adiposity and risk of death in Europe. *N Engl J Med*. 2008;359:2105–2120.
19. Flegal KM, Graubard BI. Estimates of excess deaths associated with body mass index and other anthropometric variables. *Am J Clin Nutr*. 2009;89:1213–1219.
20. Evans A, Salomaa V, Kulathinal S, Asplund K, Cambien F, Ferrario M, Perola M, Peltonen L, Shields D, Tunstall-Pedoeet H, et al. MORGAM (an international pooling of cardiovascular cohorts). *Int J Epidemiol*. 2005;34:21–27.
21. MORGAM Project. Description and quality assessment of MORGAM data. 2008. <https://thl.fi/publications/morgam/qa/baseline/contents.htm>. Accessed March 13, 2019.
22. Kulathinal S, Niemelä M, Niiranen T, Saarela O, Palosaari T, Tapanainen H, Kuulasmaa K. Description of MORGAM cohorts. MORGAM Project

- 
- e-publications [Internet]. 2005. (2). URN:NBN:fi-fe20051214. <https://thl.fi/publications/morgam/cohorts/index.html>. Accessed April 6, 2020.
23. World Health Organization (WHO). WHO MONICA Project e-publications (ISSN 2242-1246), No. 1.5. 1999. <http://www.thl.fi/publications/monica/manual/part1/i-2.htm>. URN:NBN:fi-fe19981148. Accessed March 13, 2019.
  24. MORGAM Project. MORGAM manual. MORGAM Project e-publications [Internet]. 2001; (1). URN:NBN:fi-fe20041529. <https://thl.fi/publications/morgam/manual/contents.htm>. Accessed April 6, 2020.
  25. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation*. 2008;117:743–753.
  26. Lanfer A, Mehlig K, Heitmann BL, Lissner L. Does change in hip circumference predict cardiovascular disease and overall mortality in Danish and Swedish women? *Obesity (Silver Spring)*. 2014;22:957–963.
  27. Cameron AJ, Magliano DJ, Shaw JE, Zimmet PZ, Carstensen B, Alberti KG, Tuomilehto J, Barr EL, Pauvaday VK, Kowlessur S, et al. The influence of hip circumference on the relationship between abdominal obesity and mortality. *Int J Epidemiol*. 2012;41:484–494.
  28. Dunstan DW, Barr EL, Healy GN, Salmon J, Shaw JE, Balkau B, Magliano DJ, Cameron AJ, Zimmet PZ, Owen N. Television viewing time and mortality: the Australian Diabetes, Obesity and Lifestyle Study (AusDiab). *Circulation*. 2010;121:384–391.
  29. Bellavia A, Bottai M, Wolk A, Orsini N. Physical activity and mortality in a prospective cohort of middle-aged and elderly men—a time perspective. *Int J Behav Nutr Phys Act*. 2013;10:94.
  30. Ostergaard JN, Gronbaek M, Angquist L, Schnohr P, Sorensen TI, Heitmann BL. Combined influence of leisure-time physical activity and hip circumference on all-cause mortality. *Obesity (Silver Spring)*. 2013;21:E78–E85.

# **Supplemental Material**

**Table S1. Range of values for obesity measure categories by sex .**

Obesity Measure	CATEGORY					
	<-1SD below the mean	-1 to <-½SD below the mean	≥-½ to ≤½SD from the mean	>½ to 1SD above the mean	>1 to 2SD above the mean	>2SD above the mean
<b>Body mass index (kg/m<sup>2</sup>)<sup>+</sup></b>						
Females	<21.8	21.8 - <24.3	24.3 - 29.4	>29.4 - 32.0	>32.0 - 37.1	>37.1
Males	<23.3	23.3 - <25.2	25.2 - 29.0	>29.0 - 30.9	>30.9 - 34.8	>34.8
<b>Waist-to-hip ratio</b>						
Females	<0.76	0.76 - <0.80	0.80 - 0.87	>0.87 - 0.91	>0.91 - 0.99	>0.99
Males	<0.88	0.88 - <0.91	0.91 - 0.97	>0.97 - 1.01	>1.01 - 1.07	>1.07
<b>A body shape index<sup>†</sup></b>						
Females	<0.070	0.070 - <0.073	0.073 - 0.079	>0.079 - 0.082	>0.082 - 0.088	>0.088
Males	<0.076	0.076 - <0.078	0.078 - 0.083	>0.083 - 0.085	>0.085 - 0.089	>0.089
<b>Waist-to-height ratio</b>						
Females	<0.45	0.45 - <0.49	0.49 - 0.58	>0.58 - 0.63	>0.63 - 0.71	>0.71
Males	<0.49	0.49 - <0.52	0.52 - 0.58	>0.58 - 0.61	>0.61 - 0.68	>0.68
<b>Waist circumference (cm)</b>						
Females	<72.8	72.8 - <79.3	79.3 - 92.3	>92.3 - 98.8	>98.8 - 111.8	>111.8
Males	<84.8	84.8 - <90.0	90.0 - 100.5	>100.5 - 105.7	>105.7 - 116.2	>116.2
<b>Hip circumference (cm)</b>						
Females	<92.5	92.5 - <97.6	97.6 - 107.7	>107.7 - 112.8	>112.8 - 123.0	>123.0
Males	<93.3	93.3 - <97.2	97.2 - 104.8	>104.8 - 108.6	>108.6 - 116.2	>116.2

<sup>+</sup> Body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.

<sup>†</sup> A body shape index is waist circumference in metres/(BMI<sup>2/3</sup> \*height in meters<sup>1/2</sup>).



**Table S2. Number and proportion of participants in each combination of hip and waist circumference categories, by sex.**

Waist circumference	HIP CIRCUMFERENCE											
	<-1SD below the mean		-1 to <-½SD below the mean		≥-½ to ≤½SD from the mean		>½ to 1SD above the mean		>1 to 2SD above the mean		>2SD above the mean	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
<b>FEMALES (N=42,792)</b>												
<-1SD below the mean	3,528	(8.2)	2,282	(5.3)	880	(2.1)	23	(0.054)	2	(0.0047)	0	(0)
-1 to <-½SD below the mean	1,508	(3.5)	3,344	(7.8)	3,486	(8.1)	142	(0.33)	18	(0.042)	1	(0.0023)
≥-½ to ≤½SD from the mean	623	(1.5)	2,443	(5.7)	9,548	(22)	2,163	(5.1)	709	(1.7)	21	(0.049)
>½ to 1SD above the mean	33	(0.077)	207	(0.48)	2,136	(5.0)	1,406	(3.3)	1,245	(2.9)	101	(0.24)
>1 to 2SD above the mean	23	(0.054)	75	(0.18)	1,217	(2.8)	1,206	(2.8)	2,060	(4.8)	726	(1.7)
>2SD above the mean	1	(0.0023)	7	(0.016)	67	(0.16)	125	(0.29)	552	(1.3)	884	(2.1)
<b>MALES (N=47,695)</b>												
<-1SD below the mean	3,718	(7.8)	2,054	(4.3)	1,115	(2.3)	30	(0.063)	5	(0.010)	0	(0)
-1 to <-½SD below the mean	1,910	(4.0)	2,964	(6.2)	3,718	(7.8)	226	(0.47)	50	(0.10)	2	(0.0042)
≥-½ to ≤½SD from the mean	965	(2.0)	3,034	(6.4)	11,020	(23)	2,852	(6.0)	747	(1.6)	23	(0.048)
>½ to 1SD above the mean	39	(0.082)	207	(0.43)	2,587	(5.4)	2,120	(4.4)	1,285	(2.7)	39	(0.082)
>1 to 2SD above the mean	11	(0.023)	49	(0.10)	906	(1.9)	1,478	(3.1)	2,577	(5.4)	462	(1.0)
>2SD above the mean	0	(0)	1	(0.0021)	37	(0.078)	87	(0.18)	506	(1.1)	871	(1.8)

**Table S3. Summary of follow-up times, mortality rates and baseline characteristics of participants included in and excluded from the analysis sample.**

Characteristic	Analysis Sample <sup>^</sup> (N=90,487)		Excluded from analysis sample <sup>s</sup> (N=6,702)			
	n	(%)	N <sup>†</sup>	(%) <sup>#</sup>	n	(%)
<b>Survival</b>						
All-cause deaths	9,105	(10.1)	6,702	(100)	777	(11.6)
CVD deaths	2,577	(2.8)	6,702	(100)	241	(3.6)
Median (IQR) follow-up (years)	10.0	(10.4)	6,702	(100)	9.5	(6.8)
Mean (SD) age died/censored (years)	63.1	(11.4)	6,702	(100)	63.6	(11.1)
<b>Demographics</b>						
Male	47,695	(52.7)	6,702	(100)	2,966	(44.3)
Mean (SD) age (years)	52.0	(10.8)	6,702	(100)	52.4	(10.4)
Age (years)			6,702	(100)		
<50	36,798	(40.7)			2,131	(31.8)
50 - <55	15,739	(17.4)			1,997	(29.8)
55 - <60	16,413	(18.1)			1,126	(16.8)
60 - <65	10,468	(11.6)			651	(9.7)
65 - <70	6,561	(7.3)			428	(6.4)
70 - <75	4,508	(5.0)			369	(5.5)
<b>Body measurements</b>						
Body mass index			5,924	(88.4)		
<-1SD below the mean	12,587	(13.9)			831	(14.0)
-1 to <-½SD below the mean	17,793	(19.7)			1,196	(20.2)
≥-½ to ≤½SD from the mean	36,066	(39.9)			2,315	(39.1)
>½ to 1SD above the mean	10,744	(11.9)			678	(11.4)
>1 to 2SD above the mean	9,803	(10.8)			649	(11.0)
>2SD above the mean	3,494	(3.9)			255	(4.3)
Waist-to-hip ratio			3,918	(58.5)		
<-1SD below the mean	12,661	(14.0)			377	(9.6)
-1 to <-½SD below the mean	17,454	(19.3)			586	(15.0)
≥-½ to ≤½SD from the mean	34,932	(38.6)			1,598	(40.8)
>½ to 1SD above the mean	11,901	(13.2)			585	(14.9)
>1 to 2SD above the mean	10,535	(11.6)			587	(15.0)
>2SD above the mean	3,004	(3.3)			185	(4.7)
A body shape index <sup>†</sup>			3,854	(57.5)		
<-1SD below the mean	13,037	(14.4)			530	(13.8)
-1 to <-½SD below the mean	15,582	(17.2)			696	(18.1)
≥-½ to ≤½SD from the mean	36,221	(40.0)			1,560	(40.5)
>½ to 1SD above the mean	11,947	(13.2)			546	(14.2)
>1 to 2SD above the mean	10,810	(11.9)			397	(10.3)
>2SD above the mean	2,890	(3.2)			125	(3.2)
Waist-to-height ratio			3,878	(57.9)		
<-1SD below the mean	14,002	(15.5)			549	(14.2)
-1 to <-½SD below the mean	16,583	(18.3)			675	(17.4)
≥-½ to ≤½SD from the mean	34,394	(38.0)			1,456	(37.5)
>½ to 1SD above the mean	11,571	(12.8)			524	(13.5)
>1 to 2SD above the mean	10,722	(11.8)			494	(12.7)
>2SD above the mean	3,215	(3.6)			180	(4.6)
Waist circumference			3,948	(58.9)		
<-1SD below the mean	13,637	(15.1)			535	(13.6)
-1 to <-½SD below the mean	17,369	(19.2)			713	(18.1)
≥-½ to ≤½SD from the mean	34,148	(37.7)			1,433	(36.3)
>½ to 1SD above the mean	11,405	(12.6)			540	(13.7)
>1 to 2SD above the mean	10,790	(11.9)			524	(13.3)
>2SD above the mean	3,138	(3.5)			203	(5.1)
Hip circumference			3,930	(58.6)		
<-1SD below the mean	12,359	(13.7)			640	(16.3)
-1 to <-½SD below the mean	16,667	(18.4)			733	(18.7)

≥-½ to ≤½SD from the mean	36,717 (40.6)		1,455 (37.0)
>½ to 1SD above the mean	11,858 (13.1)		515 (13.1)
>1 to 2SD above the mean	9,756 (10.8)		409 (10.4)
>2SD above the mean	3,130 (3.5)		178 (4.5)
<b>Other vascular risk factors</b>			
Mean (SD) total cholesterol (mmol/l)	5.81 (1.15)	5,690 (84.9)	6.06 (1.26)
Median (IQR) total cholesterol (mmol/l)	5.70 (1.50)	5,690 (84.9)	5.90 (1.60)
Mean (SD) HDL cholesterol (mmol/l)	1.43 (0.40)	5,591 (83.4)	1.52 (0.43)
Median (IQR) HDL cholesterol (mmol/l)	1.39 (0.50)	5,591 (83.4)	1.47 (0.56)
Mean (SD) systolic blood pressure (mm Hg)	136 (21)	6,011 (89.7)	141 (21)
Taking antihypertensive drugs	14,367 (15.9)	4,202 (62.7)	538 (12.8)
Current daily smoker	22,545 (24.9)	6,587 (98.3)	1,889 (28.7)
Diabetes	4,028 (4.5)	5,797 (86.5)	232 (4.0)

<sup>^</sup> Included in the analysis sample, complete data for all analysis measures.

<sup>§</sup> Excluded from the analysis sample, missing data for one of more of the analysis variables.

<sup>¥</sup> Number of participants with incomplete data who had data for the measure. For ordinal measures, sample size shown next to variable name.

<sup>#</sup> Percent of participants with incomplete data who had data for the measure. For ordinal measures percent shown next to variable name

<sup>&</sup> Body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.

<sup>†</sup> A body shape index is waist circumference in metres/(BMI<sup>2/3</sup> \*height in meters<sup>1/2</sup>).

**Table S4. Estimated risk of death from all-causes among females (N=42,792) according to categorical body measurement categories under partial and full adjustment<sup>s</sup>**

Body measurement	Number of people	Number of deaths	Partially adjusted <sup>#</sup>			Further adjusted <sup>&amp;</sup>		
			HR	(95% CI)	p-value	HR	(95% CI)	p-value
<b>Body mass index (kg/m<sup>2</sup>)<sup>+</sup></b>								
<-1SD below the mean	5,935	417	1.44	(1.28 - 1.61)	4 x 10 <sup>-20</sup>	1.40	(1.25 - 1.58)	8 x 10 <sup>-12</sup>
-1 to <-½SD below the mean	9,126	602	1.13	(1.02 - 1.25)		1.15	(1.04 - 1.27)	
≥-½ to ≤½SD from the mean	16,325	1,219	1.00			1.00		
>½ to 1SD above the mean	4,780	437	1.16	(1.04 - 1.29)		1.09	(0.98 - 1.22)	
>1 to 2SD above the mean	4,859	470	1.43	(1.28 - 1.59)		1.29	(1.16 - 1.44)	
>2SD above the mean	1,767	177	1.84	(1.57 - 2.16)		1.54	(1.31 - 1.81)	
<b>Waist-to-hip ratio</b>								
<-1SD below the mean	6,148	338	0.79	(0.70 - 0.89)	4 x 10 <sup>-26</sup>	0.87	(0.77 - 0.98)	1 x 10 <sup>-12</sup>
-1 to <-½SD below the mean	8,125	599	0.88	(0.80 - 0.97)		0.93	(0.84 - 1.02)	
≥-½ to ≤½SD from the mean	16,988	1,457	1.00			1.00		
>½ to 1SD above the mean	5,229	488	1.30	(1.17 - 1.44)		1.23	(1.11 - 1.37)	
>1 to 2SD above the mean	4,618	349	1.53	(1.36 - 1.72)		1.40	(1.24 - 1.58)	
>2SD above the mean	1,684	91	1.82	(1.45 - 2.27)		1.60	(1.28 - 2.00)	
<b>A body shape index<sup>†</sup></b>								
<-1SD below the mean	5,992	332	0.71	(0.63 - 0.80)	5 x 10 <sup>-29</sup>	0.78	(0.68 - 0.88)	2 x 10 <sup>-17</sup>
-1 to <-½SD below the mean	8,248	534	0.79	(0.71 - 0.87)		0.83	(0.75 - 0.91)	
≥-½ to ≤½SD from the mean	16,983	1,495	1.00			1.00		
>½ to 1SD above the mean	4,818	495	1.29	(1.16 - 1.43)		1.19	(1.08 - 1.33)	
>1 to 2SD above the mean	4,932	372	1.39	(1.23 - 1.56)		1.32	(1.17 - 1.48)	
>2SD above the mean	1,819	94	1.90	(1.52 - 2.38)		1.74	(1.39 - 2.18)	
<b>Waist-to-height ratio</b>								
<-1SD below the mean	6,862	374	1.04	(0.92 - 1.17)	1 x 10 <sup>-23</sup>	1.05	(0.93 - 1.19)	6 x 10 <sup>-12</sup>
-1 to <-½SD below the mean	8,514	592	0.99	(0.90 - 1.10)		1.01	(0.91 - 1.11)	
≥-½ to ≤½SD from the mean	15,219	1,258	1.00			1.00		
>½ to 1SD above the mean	5,264	473	1.19	(1.07 - 1.33)		1.12	(1.01 - 1.25)	
>1 to 2SD above the mean	5,290	494	1.56	(1.40 - 1.74)		1.43	(1.28 - 1.59)	
>2SD above the mean	1,643	131	2.09	(1.73 - 2.51)		1.72	(1.43 - 2.08)	
<b>Waist circumference (cm)</b>								
<-1SD below the mean	6,715	393	1.09	(0.97 - 1.23)	4 x 10 <sup>-28</sup>	1.10	(0.98 - 1.24)	7 x 10 <sup>-15</sup>
-1 to <-½SD below the mean	8,499	600	1.00	(0.91 - 1.10)		1.03	(0.93 - 1.13)	
≥-½ to ≤½SD from the mean	15,507	1,227	1.00			1.00		
>½ to 1SD above the mean	5,128	459	1.20	(1.08 - 1.34)		1.14	(1.02 - 1.27)	
>1 to 2SD above the mean	5,307	492	1.51	(1.36 - 1.68)		1.40	(1.26 - 1.56)	
>2SD above the mean	1,636	151	2.32	(1.95 - 2.75)		1.92	(1.61 - 2.29)	
<b>Hip circumference (cm)</b>								
<-1SD below the mean	5,716	414	1.52	(1.35 - 1.71)	4 x 10 <sup>-20</sup>	1.45	(1.29 - 1.63)	7 x 10 <sup>-13</sup>
-1 to <-½SD below the mean	8,358	549	1.14	(1.03 - 1.26)		1.15	(1.04 - 1.28)	
≥-½ to ≤½SD from the mean	17,334	1,251	1.00			1.00		
>½ to 1SD above the mean	5,065	433	1.07	(0.96 - 1.20)		1.03	(0.92 - 1.15)	
>1 to 2SD above the mean	4,586	491	1.39	(1.25 - 1.54)		1.29	(1.16 - 1.43)	
>2SD above the mean	1,733	184	1.71	(1.46 - 2.00)		1.47	(1.25 - 1.72)	
<b>Waist &amp; hip circumference</b>								
<b>Waist</b>								
<-1SD below the mean	6,715	393	0.72	(0.62 - 0.83)	2 x 10 <sup>-24</sup>	0.79	(0.68 - 0.91)	2 x 10 <sup>-13</sup>
-1 to <-½SD below the mean	8,499	600	0.83	(0.74 - 0.92)		0.88	(0.79 - 0.98)	
≥-½ to ≤½SD from the mean	15,507	1,227	1.00			1.00		
>½ to 1SD above the mean	5,128	459	1.30	(1.15 - 1.46)		1.21	(1.08 - 1.37)	
>1 to 2SD above the mean	5,307	492	1.67	(1.46 - 1.91)		1.52	(1.32 - 1.74)	
>2SD above the mean	1,636	151	2.67	(2.14 - 3.34)		2.16	(1.72 - 2.71)	
<b>Hip</b>								
<-1SD below the mean	5,716	414	1.95	(1.69 - 2.25)	1 x 10 <sup>-18</sup>	1.72	(1.49 - 1.98)	5 x 10 <sup>-12</sup>
-1 to <-½SD below the mean	8,358	549	1.33	(1.19 - 1.48)		1.27	(1.14 - 1.42)	
≥-½ to ≤½SD from the mean	17,334	1,251	1.00			1.00		
>½ to 1SD above the mean	5,065	433	0.90	(0.80 - 1.01)		0.91	(0.81 - 1.02)	
>1 to 2SD above the mean	4,586	491	0.96	(0.84 - 1.09)		0.97	(0.85 - 1.11)	
>2SD above the mean	1,733	184	0.87	(0.71 - 1.07)		0.89	(0.72 - 1.09)	

<sup>s</sup> HR hazard ratio. CI confidence interval. Estimated separately for males and females using Cox proportional hazards models, stratified by cohort, with age at death/censoring as the time variable.

<sup>#</sup> Adjusted for age at baseline.

<sup>&</sup> Adjusted for age at baseline, log of total cholesterol (mmol/l), log of HDL cholesterol (mmol/l), systolic blood pressure (mm Hg), taking antihypertensive drugs, current daily smoker (cigarettes, cigars/cigarillos or pipe), diabetes, and an interaction between age at baseline and log of HDL cholesterol (mmol/l).

<sup>+</sup> Body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.

<sup>†</sup> A body shape index is waist circumference in metres/(BMI<sup>2/3</sup>\*height in meters<sup>1/2</sup>).

**Table S5. Estimated risk of death from all-causes among males (N= 47,695) according to categorical body measurement categories under partial and full adjustment<sup>s</sup>**

Body measurement	Number of people	Number of deaths	Partially adjusted <sup>#</sup>			Further adjusted <sup>&amp;</sup>		
			HR	(95% CI)	p-value	HR	(95% CI)	p-value
<b>Body mass index (kg/m<sup>2</sup>)<sup>+</sup></b>								
<-1SD below the mean	6,652	997	1.49	(1.38 - 1.60)	3 x 10 <sup>-36</sup>	1.34	(1.24 - 1.45)	6 x 10 <sup>-18</sup>
-1 to <-½SD below the mean	8,667	1,003	1.09	(1.01 - 1.18)		1.07	(0.99 - 1.16)	
≥-½ to ≤½SD from the mean	19,741	2,146	1.00			1.00		
>½ to 1SD above the mean	5,964	706	1.17	(1.08 - 1.28)		1.14	(1.05 - 1.24)	
>1 to 2SD above the mean	4,944	679	1.34	(1.23 - 1.46)		1.23	(1.12 - 1.34)	
>2SD above the mean	1,727	252	1.84	(1.61 - 2.10)		1.55	(1.35 - 1.77)	
<b>Waist-to-hip ratio</b>								
<-1SD below the mean	6,513	686	0.94	(0.86 - 1.03)	7 x 10 <sup>-35</sup>	0.95	(0.86 - 1.04)	2 x 10 <sup>-19</sup>
-1 to <-½SD below the mean	9,329	1,035	0.96	(0.89 - 1.04)		0.98	(0.91 - 1.06)	
≥-½ to ≤½SD from the mean	17,944	2,045	1.00			1.00		
>½ to 1SD above the mean	6,672	877	1.19	(1.10 - 1.29)		1.15	(1.06 - 1.25)	
>1 to 2SD above the mean	5,917	917	1.46	(1.35 - 1.58)		1.36	(1.26 - 1.48)	
>2SD above the mean	1,320	223	1.85	(1.61 - 2.13)		1.58	(1.37 - 1.82)	
<b>A body shape index<sup>†</sup></b>								
<-1SD below the mean	7,045	580	0.86	(0.78 - 0.95)	2 x 10 <sup>-58</sup>	0.89	(0.81 - 0.98)	8 x 10 <sup>-39</sup>
-1 to <-½SD below the mean	7,334	661	0.90	(0.83 - 0.99)		0.93	(0.85 - 1.02)	
≥-½ to ≤½SD from the mean	19,238	2,065	1.00			1.00		
>½ to 1SD above the mean	7,129	1,032	1.24	(1.15 - 1.33)		1.21	(1.12 - 1.31)	
>1 to 2SD above the mean	5,878	1,153	1.53	(1.42 - 1.65)		1.43	(1.33 - 1.54)	
>2SD above the mean	1,071	292	2.07	(1.82 - 2.34)		1.82	(1.60 - 2.06)	
<b>Waist-to-height ratio</b>								
<-1SD below the mean	7,140	764	1.16	(1.07 - 1.26)	4 x 10 <sup>-35</sup>	1.08	(0.99 - 1.18)	9 x 10 <sup>-20</sup>
-1 to <-½SD below the mean	8,069	882	1.00	(0.92 - 1.08)		1.00	(0.92 - 1.08)	
≥-½ to ≤½SD from the mean	19,175	2,161	1.00			1.00		
>½ to 1SD above the mean	6,307	841	1.16	(1.07 - 1.25)		1.15	(1.06 - 1.24)	
>1 to 2SD above the mean	5,432	835	1.38	(1.27 - 1.50)		1.29	(1.18 - 1.40)	
>2SD above the mean	1,572	300	2.03	(1.80 - 2.30)		1.75	(1.54 - 1.98)	
<b>Waist circumference (cm)</b>								
<-1SD below the mean	6,922	819	1.22	(1.13 - 1.33)	6 x 10 <sup>-32</sup>	1.13	(1.03 - 1.23)	1 x 10 <sup>-16</sup>
-1 to <-½SD below the mean	8,870	975	1.05	(0.97 - 1.13)		1.05	(0.97 - 1.13)	
≥-½ to ≤½SD from the mean	18,641	2,058	1.00			1.00		
>½ to 1SD above the mean	6,277	785	1.10	(1.01 - 1.19)		1.07	(0.98 - 1.16)	
>1 to 2SD above the mean	5,483	884	1.41	(1.30 - 1.53)		1.31	(1.21 - 1.42)	
>2SD above the mean	1,502	262	1.93	(1.70 - 2.20)		1.63	(1.43 - 1.87)	
<b>Hip circumference (cm)</b>								
<-1SD below the mean	6,643	853	1.49	(1.37 - 1.62)	2 x 10 <sup>-26</sup>	1.36	(1.25 - 1.49)	4 x 10 <sup>-16</sup>
-1 to <-½SD below the mean	8,309	921	1.10	(1.01 - 1.18)		1.06	(0.98 - 1.15)	
≥-½ to ≤½SD from the mean	19,383	2,163	1.00			1.00		
>½ to 1SD above the mean	6,793	901	1.07	(0.99 - 1.15)		1.08	(0.99 - 1.16)	
>1 to 2SD above the mean	5,170	713	1.20	(1.10 - 1.31)		1.17	(1.07 - 1.27)	
>2SD above the mean	1,397	232	1.67	(1.45 - 1.91)		1.52	(1.32 - 1.74)	
<b>Waist &amp; hip circumference</b>								
<b>Waist</b>								
<-1SD below the mean	6,922	819	0.90	(0.81 - 0.99)	1 x 10 <sup>-27</sup>	0.90	(0.81 - 0.99)	7 x 10 <sup>-13</sup>
-1 to <-½SD below the mean	8,870	975	0.92	(0.85 - 1.00)		0.95	(0.88 - 1.04)	
≥-½ to ≤½SD from the mean	18,641	2,058	1.00			1.00		
>½ to 1SD above the mean	6,277	785	1.20	(1.10 - 1.31)		1.13	(1.03 - 1.23)	
>1 to 2SD above the mean	5,483	884	1.62	(1.47 - 1.79)		1.42	(1.28 - 1.56)	
>2SD above the mean	1,502	262	2.26	(1.90 - 2.70)		1.74	(1.46 - 2.08)	
<b>Hip</b>								
<-1SD below the mean	6,643	853	1.71	(1.54 - 1.90)	6 x 10 <sup>-23</sup>	1.52	(1.37 - 1.69)	2 x 10 <sup>-12</sup>
-1 to <-½SD below the mean	8,309	921	1.20	(1.10 - 1.31)		1.13	(1.04 - 1.23)	
≥-½ to ≤½SD from the mean	19,383	2,163	1.00			1.00		
>½ to 1SD above the mean	6,793	901	0.91	(0.83 - 0.99)		0.96	(0.89 - 1.05)	
>1 to 2SD above the mean	5,170	713	0.85	(0.76 - 0.94)		0.92	(0.82 - 1.02)	
>2SD above the mean	1,397	232	0.89	(0.74 - 1.07)		1.00	(0.83 - 1.20)	

<sup>s</sup> HR hazard ratio. CI confidence interval. Estimated separately for males and females using Cox proportional hazards models, stratified by cohort, with age at death/censoring as the time variable. <sup>#</sup> Adjusted for age at baseline. <sup>&</sup> Adjusted for age at baseline, log of total cholesterol (mmol/l), log of HDL cholesterol (mmol/l), systolic blood pressure (mm Hg), taking antihypertensive drugs, current daily smoker (cigarettes, cigars/cigarillos or pipe), diabetes, and an interaction between age at baseline and current daily smoker. <sup>+</sup> Body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. <sup>†</sup> A body shape index is waist circumference in metres/(BMI<sup>2/3</sup> \*height in meters<sup>1/2</sup>).

**Table S6. Estimated risk of death from cardiovascular disease among females (N=42,792) according to categorical body measurement categories under partial and full adjustment<sup>s</sup>**

Body measurement	Number of people	Number of deaths	Partially adjusted <sup>#</sup>			Further adjusted <sup>&amp;</sup>		
			HR	(95% CI)	p-value	HR	(95% CI)	p-value
<b>Body mass index (kg/m<sup>2</sup>)<sup>+</sup></b>								
<-1SD below the mean	5,935	92	1.15	(0.90 - 1.45)	3 x 10 <sup>-10</sup>	1.22	(0.96 - 1.56)	9 x 10 <sup>-4</sup>
-1 to <-½SD below the mean	9,126	153	1.06	(0.87 - 1.28)		1.18	(0.97 - 1.43)	
≥-½ to ≤½SD from the mean	16,325	333	1.00			1.00		
>½ to 1SD above the mean	4,780	151	1.45	(1.19 - 1.76)		1.29	(1.06 - 1.57)	
>1 to 2SD above the mean	4,859	124	1.43	(1.16 - 1.76)		1.17	(0.94 - 1.44)	
>2SD above the mean	1,767	62	2.51	(1.90 - 3.30)		1.82	(1.37 - 2.41)	
<b>Waist-to-hip ratio</b>								
<-1SD below the mean	6,148	77	0.64	(0.50 - 0.82)	5 x 10 <sup>-16</sup>	0.80	(0.63 - 1.04)	3 x 10 <sup>-5</sup>
-1 to <-½SD below the mean	8,125	144	0.72	(0.60 - 0.87)		0.83	(0.69 - 1.01)	
≥-½ to ≤½SD from the mean	16,988	422	1.00			1.00		
>½ to 1SD above the mean	5,229	136	1.26	(1.04 - 1.53)		1.15	(0.94 - 1.39)	
>1 to 2SD above the mean	4,618	107	1.73	(1.40 - 2.15)		1.46	(1.18 - 1.82)	
>2SD above the mean	1,684	29	2.37	(1.60 - 3.52)		1.77	(1.19 - 2.62)	
<b>A body shape index<sup>†</sup></b>								
<-1SD below the mean	5,992	81	0.64	(0.50 - 0.82)	3 x 10 <sup>-14</sup>	0.77	(0.60 - 0.99)	6 x 10 <sup>-8</sup>
-1 to <-½SD below the mean	8,248	151	0.83	(0.69 - 1.01)		0.91	(0.75 - 1.10)	
≥-½ to ≤½SD from the mean	16,983	405	1.00			1.00		
>½ to 1SD above the mean	4,818	151	1.46	(1.21 - 1.76)		1.28	(1.06 - 1.55)	
>1 to 2SD above the mean	4,932	93	1.33	(1.06 - 1.68)		1.21	(0.96 - 1.53)	
>2SD above the mean	1,819	34	3.02	(2.09 - 4.38)		2.75	(1.89 - 3.98)	
<b>Waist-to-height ratio</b>								
<-1SD below the mean	6,862	76	0.73	(0.56 - 0.94)	8 x 10 <sup>-14</sup>	0.83	(0.64 - 1.08)	1 x 10 <sup>-3</sup>
-1 to <-½SD below the mean	8,514	139	0.79	(0.65 - 0.96)		0.87	(0.71 - 1.07)	
≥-½ to ≤½SD from the mean	15,219	370	1.00			1.00		
>½ to 1SD above the mean	5,264	147	1.30	(1.07 - 1.57)		1.11	(0.92 - 1.35)	
>1 to 2SD above the mean	5,290	146	1.65	(1.36 - 2.01)		1.36	(1.12 - 1.67)	
>2SD above the mean	1,643	37	2.37	(1.68 - 3.35)		1.63	(1.15 - 2.32)	
<b>Waist circumference (cm)</b>								
<-1SD below the mean	6,715	77	0.71	(0.55 - 0.92)	2 x 10 <sup>-15</sup>	0.80	(0.62 - 1.04)	1 x 10 <sup>-4</sup>
-1 to <-½SD below the mean	8,499	147	0.80	(0.66 - 0.97)		0.91	(0.75 - 1.11)	
≥-½ to ≤½SD from the mean	15,507	372	1.00			1.00		
>½ to 1SD above the mean	5,128	125	1.10	(0.90 - 1.35)		0.96	(0.78 - 1.18)	
>1 to 2SD above the mean	5,307	149	1.57	(1.29 - 1.90)		1.33	(1.09 - 1.61)	
>2SD above the mean	1,636	45	2.64	(1.93 - 3.62)		1.79	(1.30 - 2.47)	
<b>Hip circumference (cm)</b>								
<-1SD below the mean	5,716	100	1.35	(1.07 - 1.70)	8 x 10 <sup>-8</sup>	1.37	(1.09 - 1.74)	2 x 10 <sup>-3</sup>
-1 to <-½SD below the mean	8,358	142	1.11	(0.91 - 1.35)		1.20	(0.98 - 1.46)	
≥-½ to ≤½SD from the mean	17,334	335	1.00			1.00		
>½ to 1SD above the mean	5,065	135	1.25	(1.02 - 1.53)		1.13	(0.93 - 1.39)	
>1 to 2SD above the mean	4,586	143	1.53	(1.25 - 1.86)		1.31	(1.08 - 1.60)	
>2SD above the mean	1,733	60	2.17	(1.64 - 2.86)		1.66	(1.25 - 2.20)	
<b>Waist &amp; hip circumference</b>								
<b>Waist</b>								
<-1SD below the mean	6,715	77	0.43	(0.32 - 0.59)	1 x 10 <sup>-12</sup>	0.53	(0.39 - 0.73)	5 x 10 <sup>-5</sup>
-1 to <-½SD below the mean	8,499	147	0.64	(0.52 - 0.79)		0.75	(0.61 - 0.94)	
≥-½ to ≤½SD from the mean	15,507	372	1.00			1.00		
>½ to 1SD above the mean	5,128	125	1.16	(0.93 - 1.45)		0.99	(0.79 - 1.23)	
>1 to 2SD above the mean	5,307	149	1.65	(1.29 - 2.11)		1.34	(1.04 - 1.72)	
>2SD above the mean	1,636	45	2.77	(1.84 - 4.18)		1.76	(1.16 - 2.66)	
<b>Hip</b>								
<-1SD below the mean	5,716	100	2.30	(1.73 - 3.06)	1 x 10 <sup>-6</sup>	1.97	(1.48 - 2.62)	3 x 10 <sup>-4</sup>
-1 to <-½SD below the mean	8,358	142	1.46	(1.18 - 1.81)		1.41	(1.14 - 1.75)	
≥-½ to ≤½SD from the mean	17,334	335	1.00			1.00		
>½ to 1SD above the mean	5,065	135	1.03	(0.83 - 1.27)		1.04	(0.84 - 1.29)	
>1 to 2SD above the mean	4,586	143	1.02	(0.80 - 1.30)		1.06	(0.83 - 1.36)	
>2SD above the mean	1,733	60	1.03	(0.71 - 1.50)		1.12	(0.77 - 1.62)	


<sup>s</sup> HR hazard ratio. CI confidence interval. Estimated separately for males and females using Cox proportional hazards models, stratified by cohort, with age at death/censoring as the time variable. <sup>#</sup> Adjusted for age at baseline. <sup>&</sup> Adjusted for age at baseline, log of total cholesterol (mmol/l), log of HDL cholesterol (mmol/l), systolic blood pressure (mm Hg), taking antihypertensive drugs, current daily smoker (cigarettes, cigars/cigarillos or pipe), diabetes, and an interaction between age at baseline and systolic blood pressure. <sup>+</sup> Body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. <sup>†</sup> A body shape index is waist circumference in metres/(BMI<sup>2/3</sup> \*height in meters<sup>1/2</sup>).

**Table S7. Estimated risk of death from cardiovascular disease among males (N= 47,695) according to categorical body measurement categories under partial and full adjustment<sup>s</sup>**


Body measurement	Number of people	Number of deaths	Partially adjusted <sup>#</sup>			Further adjusted <sup>&amp;</sup>		
			HR	(95% CI)	p-value	HR	(95% CI)	p-value
<b>Body mass index (kg/m<sup>2</sup>)<sup>+</sup></b>								
<-1SD below the mean	6,652	212	1.07	(0.91 - 1.25)	8 x 10 <sup>-12</sup>	1.17	(0.99 - 1.37)	5 x 10 <sup>-3</sup>
-1 to <-½SD below the mean	8,667	272	0.99	(0.86 - 1.14)		1.07	(0.93 - 1.24)	
≥-½ to ≤½SD from the mean	19,741	651	1.00			1.00		
>½ to 1SD above the mean	5,964	220	1.22	(1.04 - 1.42)		1.12	(0.96 - 1.30)	
>1 to 2SD above the mean	4,944	222	1.44	(1.23 - 1.68)		1.19	(1.02 - 1.39)	
>2SD above the mean	1,727	85	2.12	(1.69 - 2.67)		1.53	(1.21 - 1.93)	
<b>Waist-to-hip ratio</b>								
<-1SD below the mean	6,513	170	0.78	(0.65 - 0.93)	2 x 10 <sup>-26</sup>	0.93	(0.78 - 1.11)	3 x 10 <sup>-9</sup>
-1 to <-½SD below the mean	9,329	235	0.73	(0.63 - 0.85)		0.81	(0.69 - 0.94)	
≥-½ to ≤½SD from the mean	17,944	607	1.00			1.00		
>½ to 1SD above the mean	6,672	280	1.30	(1.13 - 1.50)		1.21	(1.04 - 1.39)	
>1 to 2SD above the mean	5,917	300	1.64	(1.42 - 1.89)		1.40	(1.21 - 1.62)	
>2SD above the mean	1,320	70	2.04	(1.59 - 2.63)		1.50	(1.16 - 1.93)	
<b>A body shape index<sup>†</sup></b>								
<-1SD below the mean	7,045	160	0.88	(0.74 - 1.06)	1 x 10 <sup>-24</sup>	1.01	(0.84 - 1.21)	2 x 10 <sup>-15</sup>
-1 to <-½SD below the mean	7,334	151	0.74	(0.62 - 0.88)		0.79	(0.66 - 0.94)	
≥-½ to ≤½SD from the mean	19,238	600	1.00			1.00		
>½ to 1SD above the mean	7,129	293	1.20	(1.04 - 1.38)		1.16	(1.01 - 1.34)	
>1 to 2SD above the mean	5,878	367	1.65	(1.44 - 1.88)		1.51	(1.32 - 1.73)	
>2SD above the mean	1,071	91	2.21	(1.77 - 2.77)		1.94	(1.55 - 2.44)	
<b>Waist-to-height ratio</b>								
<-1SD below the mean	7,140	167	0.96	(0.80 - 1.14)	6 x 10 <sup>-30</sup>	1.08	(0.90 - 1.30)	4 x 10 <sup>-11</sup>
-1 to <-½SD below the mean	8,069	208	0.84	(0.72 - 0.99)		0.93	(0.79 - 1.09)	
≥-½ to ≤½SD from the mean	19,175	606	1.00			1.00		
>½ to 1SD above the mean	6,307	294	1.44	(1.25 - 1.66)		1.31	(1.14 - 1.51)	
>1 to 2SD above the mean	5,432	281	1.66	(1.44 - 1.92)		1.40	(1.21 - 1.62)	
>2SD above the mean	1,572	106	2.66	(2.16 - 3.29)		1.95	(1.58 - 2.42)	
<b>Waist circumference (cm)</b>								
<-1SD below the mean	6,922	187	1.00	(0.85 - 1.18)	9 x 10 <sup>-21</sup>	1.11	(0.94 - 1.32)	9 x 10 <sup>-7</sup>
-1 to <-½SD below the mean	8,870	228	0.86	(0.74 - 1.00)		0.94	(0.80 - 1.09)	
≥-½ to ≤½SD from the mean	18,641	600	1.00			1.00		
>½ to 1SD above the mean	6,277	260	1.23	(1.07 - 1.43)		1.13	(0.97 - 1.31)	
>1 to 2SD above the mean	5,483	298	1.60	(1.39 - 1.84)		1.35	(1.17 - 1.55)	
>2SD above the mean	1,502	89	2.27	(1.81 - 2.84)		1.69	(1.35 - 2.13)	
<b>Hip circumference (cm)</b>								
<-1SD below the mean	6,643	192	1.25	(1.06 - 1.49)	2 x 10 <sup>-9</sup>	1.31	(1.10 - 1.56)	5 x 10 <sup>-5</sup>
-1 to <-½SD below the mean	8,309	244	1.03	(0.88 - 1.19)		1.07	(0.92 - 1.24)	
≥-½ to ≤½SD from the mean	19,383	627	1.00			1.00		
>½ to 1SD above the mean	6,793	282	1.13	(0.98 - 1.30)		1.09	(0.94 - 1.25)	
>1 to 2SD above the mean	5,170	235	1.36	(1.17 - 1.58)		1.21	(1.04 - 1.41)	
>2SD above the mean	1,397	82	2.04	(1.62 - 2.58)		1.68	(1.33 - 2.12)	
<b>Waist &amp; hip circumference</b>								
<b>Waist</b>								
<-1SD below the mean	6,922	187	0.73	(0.59 - 0.89)	2 x 10 <sup>-16</sup>	0.88	(0.72 - 1.09)	7 x 10 <sup>-5</sup>
-1 to <-½SD below the mean	8,870	228	0.75	(0.63 - 0.88)		0.85	(0.72 - 1.00)	
≥-½ to ≤½SD from the mean	18,641	600	1.00			1.00		
>½ to 1SD above the mean	6,277	260	1.36	(1.16 - 1.59)		1.20	(1.02 - 1.40)	
>1 to 2SD above the mean	5,483	298	1.85	(1.55 - 2.20)		1.46	(1.22 - 1.73)	
>2SD above the mean	1,502	89	2.55	(1.87 - 3.47)		1.70	(1.25 - 2.32)	
<b>Hip</b>								
<-1SD below the mean	6,643	192	1.72	(1.39 - 2.12)	6 x 10 <sup>-6</sup>	1.51	(1.22 - 1.87)	3 x 10 <sup>-3</sup>
-1 to <-½SD below the mean	8,309	244	1.26	(1.07 - 1.48)		1.19	(1.01 - 1.39)	
≥-½ to ≤½SD from the mean	19,383	627	1.00			1.00		
>½ to 1SD above the mean	6,793	282	0.88	(0.75 - 1.02)		0.94	(0.81 - 1.10)	
>1 to 2SD above the mean	5,170	235	0.84	(0.70 - 1.02)		0.92	(0.76 - 1.11)	
>2SD above the mean	1,397	82	0.96	(0.70 - 1.32)		1.11	(0.81 - 1.52)	

<sup>s</sup> HR hazard ratio. CI confidence interval. Estimated separately for males and females using Cox proportional hazards models, stratified by cohort, with age at death/censoring as the time variable. <sup>#</sup> Adjusted for age at baseline. <sup>&</sup> Adjusted for age at baseline, log of total cholesterol (mmol/l), log of HDL cholesterol (mmol/l), systolic blood pressure (mm Hg), taking antihypertensive drugs, current daily smoker (cigarettes, cigars/cigarillos or pipe), diabetes, and an interaction between age at baseline and current daily smoker. <sup>+</sup> Body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. <sup>†</sup> A body shape index is waist circumference in metres/(BMI<sup>2/3</sup>\*height in meters<sup>1/2</sup>).

Figure S1. Risk of all-cause death according to obesity measures by sex and daily smoking status for all participants, estimated after adjustment for cardiovascular risk factors.







Hazard ratios for all-cause death by sex (panel A = Female; panel B = Male), with 95% confidence intervals, are shown for each obesity measure: BMI (body mass index - the weight in kilograms divided by the square of the height in meters), WHR (weight-to-hip ratio), ABSI (a body shape index: waist circumference in metres/(BMI<sup>2/3</sup> \*height in meters<sup>1/2</sup>)), WHtR (weight-to-height ratio), WC and HC). Vertical lines indicate 95% confidence intervals. Reference category for each obesity measure was  $-1/2$  standard deviation (SD) to  $1/2$ SD from the sample sex-specific mean calculated using all participants. Risks were estimated from Cox proportional hazards models, stratified by cohort, and adjusted for age at baseline, log of total cholesterol (mmol/l), log of high density lipoprotein (HDL) cholesterol (mmol/l), systolic blood pressure (mm Hg), taking antihypertensive drugs, diabetes, current daily smoker and interaction between obesity measure and current daily smoker, and all interactions between age and other baseline measures that were statistically significant ( $p < 0.001$ ). † Additionally adjusted for an interaction between age at baseline and log of HDL cholesterol (mmol/l). <sup>‡</sup> Additionally adjusted for an interaction between age at baseline and current daily smoker. <sup>#</sup> Estimates do not include main effect of smoking to make the risk comparable to the non-smokers.